214 filings
8-K
OPTN
OptiNose Inc
15 Mar 24
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
3:36pm
8-K
OPTN
OptiNose Inc
14 Mar 24
Entry into a Material Definitive Agreement
4:27pm
8-K
OPTN
OptiNose Inc
8 Mar 24
Entry into a Material Definitive Agreement
4:10pm
S-8
OPTN
OptiNose Inc
7 Mar 24
Registration of securities for employees
4:32pm
10-K
2023 FY
OPTN
OptiNose Inc
Annual report
7 Mar 24
7:01am
8-K
eosim6
7 Mar 24
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
8-K
z4rmemk01tx4 kcp9xaf
23 Feb 24
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
7:08am
8-K
d01pz6vlkjwt3r
21 Dec 23
Entry into a Material Definitive Agreement
4:11pm
8-K
ss3yptnfj6
6 Dec 23
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
7:02am
8-K
1nb0pq28
9 Nov 23
Optinose Reports Third Quarter 2023 Financial Results
7:02am
EFFECT
osxqrri apr
18 Aug 23
Notice of effectiveness
12:15am
UPLOAD
au2u9901mdgue
15 Aug 23
Letter from SEC
12:00am
CORRESP
rg3fdbmmfc0aoi4 fi
15 Aug 23
Correspondence with SEC
12:00am
8-K
h6t8opw24l6mwvl
10 Aug 23
Optinose Reports Second Quarter 2023 Financial Results
7:02am
8-K
o99z9eaexfktaf07k9t
27 Jul 23
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
7:27am
8-K
tnt5 f85oegsjzekhz0
13 Jun 23
Departure of Directors or Certain Officers
4:35pm